8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM8-KCURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 1, 2020 (August 25, 2020)

NANOPHASETECHNOLOGIES CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	0-22333	36-3687863
(State or other	(Commission	(IRS Employer
jurisdiction of incorporation)	File Number)	Identification No.)

1319 Marquette Drive, Romeoville, Illinois60446

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (630) 771-6700

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title<br> of each class	Trading<br> Symbol(s)	Name<br> of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01	Entry into a Material Definitive Agreement.

On August 25, 2020, Nanophase Technologies Corporation, through its wholly owned subsidiary Solésence, LLC (“Solésence”) entered into an amendment #1 (the “Amendment”) to the Amended and Restated Joint Development and Supply Agreement, dated May 15, 2018 (the “Agreement”), between Solésence and Colorescience Inc. Pursuant to the Amendment, the parties agreed, among other things, to amend certain provisions regarding minimum order quantities in connection with exclusivity. This summary of the Amendment is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 to this current report on Form 8-K.

Item 9.01.	Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
10.1	Amendment<br> #1, dated August 25, 2020, to the Amended and Restated Joint Development and Supply Agreement,<br> dated May 15, 2018, between Solésence, LLC and Colorescience Inc. (portions of<br> the exhibit have been omitted in reliance on Item 601(b)(ii) of Reg S-K).

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 1, 2020

NANOPHASE TECHNOLOGIES CORPORATION
By:	/s/ JESS JANKOWSKI
	Name:<br>Jess Jankowski
	Title:<br>Chief Executive Officer

NANOPHASE TECHNOLOGIES CORPORATION 8-K

Exhibit 10.1

---

AMENDMENT#1

---

JOINTDEVELOPMENT & SUPPLY AGREEMENT

---

This amendment #1 to the Amended and Restated Joint Development & Supply Agreement ("Agreement') is made this 25th day of August 2020 ("Effective Date") between COLORESCIENCE Inc., a company existing and organized under the laws of Delaware, ("COLORESCIENCE') with its principal place of business at 2141 Palomar Airport Road, Suite 200, Carlsbad, CA 92011, and SOLESENCE, LLC, a company existing and organized under the laws of Delaware, with its principal place of business at 1319 Marquette Drive, Romeoville, Illinois 60446 ("SOLESENCE'), (collectively, the "Parties").

---

**WHEREAS,**COLORESCIENCE and SOLESENCE entered into an amended and restated Joint Development and Supply Agreement dated May 15, 2018:

**WHEREAS,**COLORESCIENCE wishes to exclusively purchase from SOLESENCE and SOLESENCE wishes to produce and sell exclusively to COLORESCIENCE the Innovation Solution Actives, and certain Finished Products.

**WHEREAS,**Minimum Order Quantities associated with Exclusivity where established in Exhibit A.

**WHEREAS,**Certain events have had an impact on Colorescience's ability optimize sales of such Finished Products including [#].

**WHEREAS,**Despite such challenges, Colorescience has invested significant resources and focus into prioritizing the Finished Products in the Colorescience portfolio and is expected to continue to purchase over [#] in Solesence Finished Products. Further, Colorescience commits to continuing to launch additional Finished Products from Solesence, with a commitment to launch at least [#] in [#] pending that the products meet the company's standards and timing for launch [#].

NowTherefore, both parties wish to amend the following provisions of the Amended Joint Development and Supply Agreement dated May 18, 2018:

Section1.4 (ii) shall be modified to reflect the following changes in its entirety

“With Respect to Finished Product A, Finished Product B, Any Next Gen Products, and Any Solution Actives which do NOT utilize the Exclusive Application: [#].”

Section2.7 shall be added to the Agreement and adopted with the following provision. “Colorescience will launch at least [#] products from Solesence in [#] as long as such products are developed according to quality standards [#] and experience between the two parties. The new products may include [#].”

3.	Section 2.8 shall be added to the Agreement. Irrespective of Exhibit A or purchase agreements,<br> it is understood by both parties that Solesence, LLC shall [#] the price offered to Colorescience<br> for [#].
4.	Section 3.7.5 shall be modified to reflect that only in [#] units sold in excess of the modified<br> Minimum Order Quantities for [#] noted in the new<br> Exhibit A below shall be credited to [#].<br> For purposes of clarity, this exception is only related to [#].<br> Thereafter the offset provision contained in Section 3.7.5 shall be applicable as reflected<br> in the original agreement.
---	---
5.	Section 7.7.2 shall be modified in part to reflect a change to the notification period from<br> [#] to [#] of<br> each year related to Exclusivity. For purposes of clarity the following provision:
---	---

“Notwithstandingthe foregoing, in the event that COLORESCIENCE does not [#] in [#] or a future year as a result of [#], COLORESCIENCE shall notify SOLESENCEof [#] by [#].”

Shallbe modified to the following: “Notwithstanding the foregoing, in the event that COLORESCIENCE does not [#] in [#] or a future year as a result [#],COLORESCIENCE shall notify SOLESENCE of [#] by [#].”

6.	Exhibit A: shall be amended and replaced in its entirety with the Exhibit A attached hereto.

All other provisions of the Joint Development and Supply Agreement dated May 15, 2018 shall remain intact and enforceable as earlier constructed.

Signed:
Colorescience, Inc:	Solesence LLC
/s/ TED EBEL	/s/ KEVIN CURETON
Ted Ebel	Kevin Cureton
Chief<br>Business Officer	Chief Commercial Officer

---

EXHIBITA

---

AnnualMinimum Order Quantities

---

	Bridge Solution — TiO2	Innovation Active Solution — TiO2	Innovation Active Solution — ZnO
Price<br> per kg	[#]	[#]	[#]
2017<br> Minimum Annual Purchases<br> (kg)	Obligations Fulfilled		[#]
2018<br> Minimum Annual Purchases<br> (kg)	Obligations<br> Fulfilled		[#]<br> (Obligations Fulfilled)
2019<br> Minimum Annual Purchases<br> (kg)	[#]<br> — combined (Obligations Fulfilled)		[#]<br> (Obligations Fulfilled)
2020<br>& beyond Minimum Annual Purchases (kg)	[#]<br> above the prior year volume,<br><br> <br>unless<br> the [#] in which case [#]<br><br> <br>is<br> sufficient		[#]<br>above the prior year volume,<br><br> <br>unless<br> [#] in which case [#]<br><br> is sufficient
Finished Products
---	---
	Finished<br> Products A ([#]) & B ([#])<br><br> <br><br><br> <br>And<br> Next Gen Products
Price<br>per Ounce	Finished<br> Product A: [#], to increase by not more than [#] per year<br><br> Finished Product B: [#], to increase by not more than [#] per year'<br><br> <br><br><br> <br>Next<br> Gen Products Prices to be negotiated
2018<br>Minimum Order Quantity (units)	[#]<br> as long as Solesence has [#]. Otherwise, the MOQ drops to [#].<br><br> <br>(ObligationFulfilled)
2019<br> Minimum Order Quantity (units)	[#]<br>(Obligation Fulfilled)
2020<br> Minimum Order Quantity (units)	[#]<br>(so long as [#])
2021<br> Minimum Order Quantity (units)	[#]<br>(so long as [#])
2022<br> Minimum Order Quantity (units)	[#]<br>(so long as [#])
2023<br> and beyond Minimum Order Quantity (units)	[#]<br>from previous year for the<br><br>duration of the Agreement
●	Price<br> per ounce for the Finished Products is, the anticipated price per ounce for<br> [#] assuming a per ounce size of [#].<br> In the event that [#], such price per ounce [#].<br> Both parties will work to identify the appropriate unit price regardless of format [#].
---	---

---